Concerns of hemolysis continued to swirl around the Sapien 3 Ultra Resilia, with yet another report indicating such harm after transcatheter aortic valve replacement (TAVR). In a single-center ...
The phase 3 PEGASUS trial found that patients with paroxysmal nocturnal hemoglobinuria (PNH) may still experience anemia following recommended therapies, underscoring the need for further research. In ...
Mean absolute fetal hemoglobin (HbF) increased by 12.2% (from 7.1% to 19.3%) at Week 12 (n=12), representing a rapid, robust, and clinically ...
Hemolysis is the destruction of red blood cells (RBCs). Typically, RBCs can live for up to 120 days before the body naturally destroys them. However, certain conditions and medications may cause them ...
BERLIN, Germany—Evidence of hemolysis was detected in the vast majority of patients undergoing pulsed-field ablation (PFA) for atrial fibrillation (AF) in a prospective study conducted at four ...
Hemolysis is a common pre-analytical variable that can lead to inaccurate results, specimen rejection, and specimen recollection in the clinical laboratory. Hemolysis is most often an in vitro ...
CHRONIC lymphocytic leukemia and malignant lymphomas of the lymphocytic and follicular types may be relatively prolonged, benign diseases. They are inevitably fatal, however, and the final years are ...
Hemolysis is the #1 source of preanalytical error and can impact potassium results—potentially leading to inappropriate or delayed patient treatment, unnecessary ...
Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results